APA (7th ed.) Citation

Jastorff, A., Bastian, A. R., Ligtenberg, N., Klyashtornyy, V., Callendret, B., & Heijnen, E. (2024, December). Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material. Human Vaccines & Immunotherapeutics.

Chicago Style (17th ed.) Citation

Jastorff, Archana, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, and Esther Heijnen. "Immunogenicity, Safety and Reactogenicity of Ad26.RSV.preF/RSV PreF Protein Vaccine in Adults Aged 60 to 75 Years: A Comparison of Phase 2b and Phase 3 Clinical Trial Material." Human Vaccines & Immunotherapeutics Dec. 2024.

MLA (9th ed.) Citation

Jastorff, Archana, et al. "Immunogenicity, Safety and Reactogenicity of Ad26.RSV.preF/RSV PreF Protein Vaccine in Adults Aged 60 to 75 Years: A Comparison of Phase 2b and Phase 3 Clinical Trial Material." Human Vaccines & Immunotherapeutics, Dec. 2024.